Document is current
Any future updates will be listed below
-
Authors
Pretz, Christopher
Fuentes-Antrás, Jesús
Main, Sasha
Dou, Aaron
Shah, Elizabeth
Van de Laar, Emily
Weipert, Caroline M.
Lin, Bryan
Das, Amar
Amir, Eitan
Nadler, Michelle B.
Yu, Celeste
Berman, Hal K.
Siu, Lillian L.
Bedard, Philippe L.
Elliott, Mitchell J.
Cescon, David W.
-
Funding
Funding for this research was provided by:
BMO Financial Group Chair in Precision Genomics at the Princess Margaret Cancer Centre through the Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE) program
Canadian Cancer Society Research Institute
Princess Margaret Cancer Foundation
Guardant Health
Fundación de la Sociedad Española de Oncología Médica
American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award
Hold'em for Life
FSEOM
NCI Experimental Therapeutics Clinical Trials Network grant
Hold'em for Life
Canadian Association of Medical Oncology (CAMO) Fellowship award
Canadian Institute of Health Research
Canadian Institutes of Health Research
ASCO Conquer Cancer Foundation/Breast Cancer Research Foundation
Komen Foundation
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 12 May 2026
First Online: 3 June 2026
Competing interests
: Christopher Pretz: Employee of Guardant Health; Jesús Fuentes-Antrás: None; Sasha Main: None; Aaron Dou: None; Elizabeth Shah: None; Emily Van de Laar: None; Caroline M. Weipert: Employee of Guardant Health; Bryan Lin: Employee of Guardant Health; Amar Das: Employee of Guardant Health; Eitan Amir: Honoraria (self): Sandoz, Seagen, Consulting (self): AstraZeneca, Novartis; Michelle B. Nadler: Speaker honorarium and consulting fees from Novartis and Exact Sciences, outside of the scope of this submitted work; Celeste Yu: None; Hal K. Berman: None; Lillian L. Siu: Scientific advisory board (self): Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea, Break Through Cancer, Clinical trial support (institution): Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Mirati, BioNTech, 23Me, EMD Serono, Stock ownership (spouse): Agios, Leadership roles (spouse): Treadwell Therapeutics; Philippe L. Bedard: Research Funding (to Institution): Amgen, AstraZeneca, Bayer, Bicara, BristolMyersSquibb, Genentech/Roche, Gilead, GlaxoSmithKline, Lilly/Loxo, Medicenna, Merck, Nektar, Novartis, PTC Therapeutics, Sanofi, SeaGen, Servier, SignalChem Life Sciences, Takeda, Zymeworks, Honoraria/Consultancy (uncompensated): Zymeworks, Lilly, Seattle Genetics, Merck, Amgen, Gilead, Jannsen, Repare; Mitchell J. Elliott: Honoraria/Consultancy: Gilead; David W. Cescon: consultancy and advisory: AstraZeneca, Daiichi Sankyo, Exact Sciences, GenomeRx, Gilead, GlaxoSmithKline, Inivata/NeoGenomics, Knight Therapeutics, Lilly, Merck, Novartis, Pfizer, Roche and SAGA; research support to institution: AstraZeneca, GenomeRx, Guardant Health, Grail, Gilead, GlaxoSmithKline, Inivata/NeoGenomics, Knight, Merck, PearBio, Pfizer, ProteinQure, RayzeBio and Roche.
